: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. Its pathogenesis encompasses functional alterations involving elevated intraglomerular and systemic pressure, increased activity of the renin-angiotensin system (RAS) and oxidative stress, and the eventual development of renal fibrosis. The management of DN involves the optimization of blood pressure (BP) and blood glucose targets. However, treatment of these risk factors slows down but does not stop the progression of DN. Innovative pharmacologic therapies for dyslipidemia and type 2 diabetes mellitus (T2DM) could play a key role in bridging this gap and attenuating the residual risk of DN beyond traditional risk factor management. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and inhibitors of mineralocorticoid receptor-mediated sodium reabsorption are recently introduced drug classes that have been shown to have positive effects on kidney function in individuals with T2DM. The aim of this review is to provide an update on the therapeutic options available in order to prevent or slow the onset and progression of DN in diabetic patients.

Giglio, R.V., Patti, A.M., Rizvi, A.A., Stoian, A.P., Ciaccio, M., Papanas, N., et al. (2023). Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update. BIOMEDICINES, 11(2) [10.3390/biomedicines11020291].

Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update

Giglio, Rosaria Vincenza;Patti, Angelo Maria;Ciaccio, Marcello;Rizzo, Manfredi
2023-01-20

Abstract

: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. Its pathogenesis encompasses functional alterations involving elevated intraglomerular and systemic pressure, increased activity of the renin-angiotensin system (RAS) and oxidative stress, and the eventual development of renal fibrosis. The management of DN involves the optimization of blood pressure (BP) and blood glucose targets. However, treatment of these risk factors slows down but does not stop the progression of DN. Innovative pharmacologic therapies for dyslipidemia and type 2 diabetes mellitus (T2DM) could play a key role in bridging this gap and attenuating the residual risk of DN beyond traditional risk factor management. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and inhibitors of mineralocorticoid receptor-mediated sodium reabsorption are recently introduced drug classes that have been shown to have positive effects on kidney function in individuals with T2DM. The aim of this review is to provide an update on the therapeutic options available in order to prevent or slow the onset and progression of DN in diabetic patients.
20-gen-2023
Giglio, R.V., Patti, A.M., Rizvi, A.A., Stoian, A.P., Ciaccio, M., Papanas, N., et al. (2023). Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update. BIOMEDICINES, 11(2) [10.3390/biomedicines11020291].
File in questo prodotto:
File Dimensione Formato  
Biomedicines 2023.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 645.87 kB
Formato Adobe PDF
645.87 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/620399
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact